Anti-TLR7 antibody or antigen binding fragment thereof, pharmaceutical composition and application thereof

By developing antibodies or antigen-binding fragments that specifically bind to TLR7, the problem of significant side effects in existing SLE treatments has been solved, achieving effective inhibition of TLR7 overactivation and providing a safer treatment option.

CN121758616APending Publication Date: 2026-03-31BEIJING SYNTHETIC VACCINE BIOSCIENCES CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202511427412.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-09-30
Filing Date
2025-09-30
Publication Date
2026-03-31

AI Technical Summary

Technical Problem

Existing treatments for SLE have significant side effects and are not curative. There is a need to develop new therapeutic drugs with fewer side effects and better efficacy, especially for autoimmune diseases caused by TLR7 overactivation.

Method used

Provide anti-TLR7 antibodies or their antigen-binding fragments that specifically bind to TLR7 to inhibit TLR7 agonist-induced cytokine release, including humanized heavy and light chain variable regions, prepared by chemical synthesis or expression systems.

Benefits of technology

It effectively inhibits TLR7 activation, reduces immune inflammatory response, and has potential applications in the treatment and prevention of various autoimmune diseases, reducing side effects and providing a long-term solution for symptom control.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.
Need to check novelty before this filing date? Find Prior Art